SLC22A6 and Patent ductus arteriosus: Due to a lack of clinical DDI data with weak and moderate OAT1/3 inhibitors and any model‐based evaluation of a DDI with OAT1/3 clinical probes, PDA is currently classified as a tier 2 biomarker [5], and hence not considered a fully validated biomarker.